Statement in response to press reports of 14 and 15 April 2017

In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Pharmacare Holdings Limited (“Aspen”) has the following comments:

  • Aspen has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception.
  • Aspen’s status as a responsible and committed provider of quality, affordable medicines is further validated by the role it has played in saving millions of lives across Africa through pioneering and supplying generic anti-retroviral medicine in Africa for the treatment of HIV/AIDS.
  • The content of the reports concern matters that are sub-judice.  Out of respect for the integrity of ongoing legal processes with European regulators, as well as the court in Italy, Aspen will not comment on these public allegations.  Instead, Aspen looks forward to the opportunity to demonstrate the integrity and legality of its practices in the context of these legal processes.












Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.